Clinical trial
Evaluation of Natalizumab for thE Relief of MS Associated FatiGue
NCT00464074 · Biogen, Industry · Completed
Key facts
| NCT number | NCT00464074 |
|---|---|
| Title | Evaluation of Natalizumab for thE Relief of MS Associated FatiGue |
| Official title | Multi-center, Open-Label Study to Evaluate the Effects of Natalizumab Treatment on Fatigue and Cognition in Subjects With Relapsing Forms of MS |
| Acronym | ENER-G |
| Lead sponsor | Biogen, Industry |
| Collaborators | Elan Pharmaceuticals Industry |
| Status | Completed |
| Study type | Observational |
| Conditions | Multiple Sclerosis |
| Enrollment | 89 |
| Start date | Aug 1, 2007 |
| Primary completion | Jul 31, 2010 |
| Completion | Jul 31, 2010 |
| First posted | Apr 20, 2007 |
| Last update posted | Aug 22, 2023 |
| Countries | Puerto Rico, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: